Management of COVID-19 Positive 45-Year-Old Woman with Isolated Sore Throat
For a 45-year-old woman with confirmed COVID-19 and only sore throat without comorbidities, supportive care with symptom management is recommended, and antiviral therapy should be considered only if she has risk factors for severe disease progression. 1
Risk Stratification and Treatment Decision
This patient does not require antiviral therapy unless she has underlying risk factors for progression to severe COVID-19 (diabetes, cardiovascular disease, immunosuppression, obesity, chronic lung disease). 1
The European League Against Rheumatism states that for non-hospitalized patients with SARS-CoV-2 infection without risk factors, there is no evidence to support immunomodulatory therapy. 1
Nirmatrelvir-ritonavir (Paxlovid) is indicated only for patients at high risk for progression to severe COVID-19 and must be initiated within 5 days of symptom onset. 2
Symptomatic Management
Sore Throat Treatment
Provide symptomatic relief for sore throat with supportive measures including adequate hydration and rest. 3
Consider povidone-iodine mouth spray as adjunctive treatment to reduce viral load in the pharynx. 4
For fever >38.5°C, ibuprofen 200 mg orally every 4-6 hours (maximum 4 times in 24 hours) can be used. 3
Nutritional Support
- Ensure protein-rich foods with ideal energy intake of 25-30 kcal/(kg·d) and protein intake of 1.5 g/(kg·d) to support immune function. 3
Monitoring and Follow-Up
Monitor for symptom progression including development of fever, cough, dyspnea, or oxygen desaturation, which would indicate need for escalation of care. 1, 3
Instruct the patient to seek immediate medical attention if she develops shortness of breath, chest pain, confusion, or inability to stay awake. 1
Complete the full isolation period per current public health recommendations to prevent transmission to others. 2
Important Clinical Pitfalls
Do not prescribe antibiotics unless there is clear evidence of bacterial superinfection; isolated sore throat with COVID-19 does not warrant empiric antibacterial therapy. 3
Avoid hydroxychloroquine as it does not provide benefit and could worsen prognosis. 1
Be aware that sore throat is a common early symptom of COVID-19, reported in mild cases, and does not by itself indicate bacterial co-infection. 5, 6
Loss of smell or taste (anosmia/ageusia), if it develops, is highly predictive of COVID-19 and associated with a seven-fold increased odds of positive testing. 6